Abstract
Background The initial evaluation of coronary stenosis during coronary angiography is typically performed by visual assessment. The visual assessment of coronary angiographies has limited accuracy compared to quantitative methods like fractional flow reserve and quantitative coronary angiography. Quantitative methods are also more time-consuming and costly.
Objectives To test whether applying deep-learning-based image analysis to coronary angiographies might yield a faster and more accurate stenosis estimation than visual assessment.
Methods We developed deep learning models for predicting coronary artery stenosis using 332,582 multi-frame x-ray images (cine loops) from 19,414 patients undergoing coronary angiography. The curated dataset for model development included 13,840 patients, with 62,165 cine loops of the left coronary artery and 31,161 cine loops of the right coronary artery.
Results For identification of significant coronary stenosis (visual assessment of diameter stenosis >70%), our model obtained a receiver operator characteristic (ROC) area under the curve (ROC-AUC) of 0.903 (95% CI: 0.900-0.906) on the internal test set with 5,056 patients. The performance was evaluated on an external test set with 608 patients against visual assessment, 3D quantitative coronary angiography, and fractional flow reserve (≤ 0.80), obtaining ROC AUC values of 0.833 (95% CI: 0.814-0.852), 0.798 (95% CI: 0.741-0.842, and 0.780 (95% CI: 0.743-0.817), respectively.
Conclusion For assessment of coronary stenosis during invasive coronary angiography a deep-learning-based model showed promising results for predicting visual assessment (ROC AUC of 0.903). Compared to previous work, our approach demonstrates performance increase, includes all 16 segments, does not exclude revascularized patients, is externally tested, and is simpler using fewer steps and fewer models.
Competing Interest Statement
Soren Brunak has ownership in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, Eli Lilly & Co and ALK Abello and has managing board memberships in Proscion A/S and Intomics A/S. Morten Bottcher declares advisory board work for Astra Zeneca, Novo Nordisk A/S, Sanofi, Bayer, Pfizer/BMS, Acarix, Boehringer Ingelheim and Novartis. The remaining authors declare no conflicts of interests.
Funding Statement
This work was funded by the Novo Nordisk Foundation (NNF17OC0027594 and NNF14CC0001) and the Innovation Fund Denmark (518-00102B).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for data access was granted by the National Committee on Health Research Ethics (1708829 "Genetics of cardiovascular disease", ID P-2019-93), The Danish Data Protection Agency (ref: 514-0255/18-3000, 514-0254/18-3000, SUND-2016-50), and by the Danish Patient Safety Authority (3-3013-1731-1, appendix 31-1522-23). All personal identifiers were pseudo-anonymized.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The author list is updated as there was a wrong ordereing here on medRxiv. There has also been an update on the title where we only use lowercase letters.
Data Availability
Data access applications can be made to the Danish Health Data Authority (contact: servicedesk{at}sundhedsdata.dk). Anyone wanting access to the data and to use them for research will be required to meet research credentialing requirements as outlined at the authority's web site: https://sundhedsdatastyrelsen.dk/da/english/health_data_and_registers/research_services. Requests are normally processed within 3 to 6 months.
